Articles
Treatment with dabrafenib and trametinib produced similar benefits in pretreated and treatment-naïve patients.
US Food and Drug Administration–approved capmatinib is an effective second-line treatment for patients with MET exon 14–mutated NSCLC.
First-line treatment with ramucirumab plus erlotinib in patients with EGFR-mutated metastatic NSCLC was associated with superior progression-free survival compared with erlotinib plus placebo.
Lorlatinib is associated with longer progression-free survival and a higher overall and intracranial response rates among patients with previously untreated, advanced ALK-positive NSCLC.
Selpercatinib and pralsetinib are US Food and Drug Administration–approved treatment options for patients with RET fusion–positive NSCLC.
[Fam-]trastuzumab deruxtecan shows promising clinical activity with a high and durable response rate in patients with HER2-mutated NSCLC.
Treatment with gefitinib in the adjuvant setting is associated with enhanced quality of life in patients with early-stage NSCLC and EGFR mutations.
Ensartinib may be a viable treatment option for some forms of secondary ALK alterations.
Similar progression-free survival and 2-year overall survival rates reported for both treatment groups, with more grade ≥3 treatment-related adverse events reported in the afatinib + cetuximab group.
Study evaluated the benefits of afatinib in Asian and non-Asian patients who had not received EGFR-TKI therapy for their EGFR-mutant NSCLC.